New shot for high blood pressure enters first human tests
NCT ID NCT07556796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a single injection of a new drug, IBI3016, in 30 Chinese adults with mild to moderate hypertension who are not currently on blood pressure medication. The main goal is to check safety and how the drug moves through the body, with a secondary look at its effect on blood pressure over about a year. It is a first step to see if the drug is safe enough for larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Chatbot could put blood pressure control in Patients' hands
- Can a 5-Step chat help tame high blood pressure?
- Can artery scans reveal hidden damage from high blood pressure?
- CRISPR injection could rewrite the future of blood pressure control
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?